Universal vaccine for viral diseases

Abstract

The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns. This universal vaccine comprises an inactivated virus with one or more of the following components: polynucleotides encoding viral peptides, polypeptides or proteins in different types of plasmids; viral peptides, polypeptides and proteins; synthetic viral peptides and polypeptides; recombinant viral peptides, polypeptides and proteins; virus-like-particles; virus-like-particles derived from other viruses; proteins used as a carrier or as molecular adjuvant fused to peptides, polypeptides and/or proteins derived from viruses; adjuvants; emulsifiers, molecular adjuvants and carrier systems.

1 - 48 . (canceled) 
     
     
         49 . A vaccine formulation capable of inducing cross-protection against different serotypes or strains of a virus, comprising whole inactivated viruses of a first serotype or strain of said Foot and Mouth Disease virus (FMDV); and recombinant or synthetic peptides, polypeptides or proteins of said FMDV. 
     
     
         50 . The vaccine formulation of  claim 49 , wherein the serotype or strain of said recombinant or synthetic peptides, polypeptides or proteins is different from said first serotype or strain. 
     
     
         51 . The vaccine formulation of  claim 49 , wherein the formulation is capable of inducing protective immunity against one or more serotypes or strains selected from the group consisting of O, A, C, Asia 1, SAT-1, SAT-2, and SAT-3. 
     
     
         52 . The vaccine formulation of  claim 49 , wherein said recombinant or synthetic peptides, polypeptides or proteins are encoded by the entire, partial or variant sequences of:
 a) amino acid sequences of FMDV capsid proteins VP1, VP2, VP3 and VP4;   b) amino acid sequences of FMDV non-structural proteins 2A, 2B, 2C, 2D, 3A, 3B, 3C and 3D;   c) amino acid sequences of one or more of SEQ ID NO. 1-55; or   d) amino acid sequences encoding peptides that are homologous or functional analogues to one or more of SEQ ID NO. 1-55.   
     
     
         53 . The vaccine formulation of  claim 49 , wherein said recombinant or synthetic peptides or polypeptides are linear or dendrimeric peptides. 
     
     
         54 . The vaccine formulation of  claim 49 , wherein said inactivated viruses are any serotype or strain of FMDV. 
     
     
         55 . The vaccine formulation of  claim 49 , wherein said recombinant or synthetic peptides, polypeptides or proteins are derived from native amino acid sequence of  Brucella  lumazine synthase (BLS) protein, its mutated variants, or amino acid sequences having at least 85% identity to the sequences of  Brucella lumazine  synthase (BLS) protein or its fragment thereof. 
     
     
         56 . The vaccine formulation of  claim 49 , wherein said recombinant or synthetic peptides, polypeptides or proteins are derived from the same or different FMDV strain(s) or serotype(s). 
     
     
         57 . The vaccine formulation of  claim 52 , wherein said recombinant or synthetic peptides, polypeptides or proteins are fused to virus-like-particles derived from other viruses. 
     
     
         58 . The vaccine formulation of  claim 57 , wherein said other viruses are selected from the group consisting of Bovine Rotavirus, BoHV-1 and BoHV-5, BPIV-3, BRSV, BVDV and Rabies Virus. 
     
     
         59 . The vaccine formulation of  claim 52 , wherein said recombinant or synthetic peptides, polypeptides or proteins are fused to carriers or molecular adjuvants. 
     
     
         60 . The vaccine formulation of  claim 49 , wherein said inactivated viruses are serotype A and said recombinant or synthetic viral peptides or polypeptides are serotype O. 
     
     
         61 . The vaccine formulation of  claim 49 , wherein said inactivated viruses are serotype O and said recombinant or synthetic viral peptides or polypeptides are serotype A. 
     
     
         62 . A method of vaccinating a host susceptible to FMDV infection, comprising administrating to the host one or more of the vaccine formulations of  claim 49  to induce an immune response. 
     
     
         63 . The method of  claim 62 , wherein the host is a cow, sheep, goat or swine. 
     
     
         64 . The method of  claim 62 , wherein the induced immune response is humoral immune response or cellular immune response. 
     
     
         65 . The method of  claim 62 , wherein the induced immune response comprises cross-protective neutralizing antibodies against two or more serotypes or strains of FMDV.